R. Scott Struthers compensation by year
Crinetics Pharmaceuticals Summary Compensation Table · all 3 fiscal years held| Component | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Salary | $614,000 | $653,833 | $718,500 |
| Bonus | — | — | $0 |
| Stock awards | $1,210,806 | $2,828,150 | $3,280,540 |
| Option awards | $3,558,849 | $6,640,800 | $7,160,564 |
| Non-equity incentive | $361,339 | $407,796 | $462,355 |
| Pension and deferred compensation | — | — | $0 |
| All other | $3,000 | $3,000 | $7,000 |
| Total | $5,747,994 | $10,533,579 | $11,628,959 |
Each year as stated in that year's proxy. A dash means the company reported no figure in that column. Source: Crinetics Pharmaceuticals, Inc. DEF 14A filed April 29, 2026, accession 0001658247-26-000030, and prior-year filings. Open the filing on EDGAR.
How this page was built: the Crinetics Pharmaceuticals, Inc. filed document, accession 0001658247-26-000030. Every figure is read from that document and cited to the page and table it appears in. Filed April 29, 2026.
Equity holdings
unvested awards at FY2024 year-end| Type | Unvested units | Value at year-end | Exercise price |
|---|---|---|---|
| RSU | 65,000 | $3,323,450 | — |
| RSU | 46,238 | $2,364,149 | — |
| RSU | 26,700 | $1,365,171 | — |
| Option | 72,684 | — | $20.02 |
| Option | 12,250 | — | $15.29 |
| Option | 195,000 | — | $43.51 |
| Option | 161,832 | — | $19.64 |
Per the Outstanding Equity Awards at Fiscal Year-End table in Crinetics Pharmaceuticals, Inc.'s FY2024 proxy; value at the fiscal year-end close, as the company printed it.
Insider transactions since the last proxy
42 Form 4 lines since the FY2025 proxy (filed April 29, 2026)current to 2026-11-07 · updated nightly
| Date | Transaction | Plan | Shares | Price | Held after |
|---|---|---|---|---|---|
| 2026-09-01 | Disposition to the issuer | — | 1,000 | $85.00 | 0 |
| 2026-09-01 | Disposition to the issuer derivative | — | 228,000 | $41.21 | 0 |
| 2026-09-01 | Disposition to the issuer | — | 136,805 | $85.00 | 0 |
| 2026-09-01 | Disposition to the issuer derivative | — | 195,578 | $62.39 | 0 |
| 2026-09-01 | Disposition to the issuer derivative | — | 240,000 | $41.49 | 0 |
| 2026-09-01 | Disposition to the issuer | — | 111,100 | $85.00 | 0 |
| 2026-09-01 | Disposition to the issuer | — | 111,100 | $85.00 | 0 |
| 2026-09-01 | Disposition to the issuer | — | 80,000 | $85.00 | 0 |
The 8 most recent of 42 lines, each as reported on the Form 4. "10b5-1" marks a trade the filing reports under a pre-arranged trading plan. View every Form 4 filing on EDGAR →
Crinetics Pharmaceuticals’s named executive officers, FY2025
as the company reported each| Named executive officer | Role | FY2025 total |
|---|---|---|
| R. Scott Struthers · this page | President, Chief Executive Officer and Director | $11,628,959 |
| Tobin Schilke | Chief Financial Officer | $4,357,893 |
| Dana Pizzuti | Chief Medical and Development Officer | $3,910,331 |
| Stephen Betz | Chief Scientific Officer | $3,827,148 |
| Jeff Knight | Chief Operating Officer | $3,826,671 |
| Marc Wilson | Former Chief Financial Officer | $3,255,392 |
Board service
Crinetics Pharmaceuticals board · FY2025How this board is paid
Company policy: Crinetics Pharmaceuticals pays directors a $41,000 cash retainer and $500,000 in Options and RSUs. As stated in Crinetics Pharmaceuticals's FY2024 proxy.
The full Crinetics Pharmaceuticals compensation record
free company briefThis page is one person within Crinetics Pharmaceuticals's record. The company brief lists every named executive, each linking to their own page.
Peer companies
named in the Crinetics Pharmaceuticals proxy · each links to its own free briefCompensation, the day it’s disclosed
The CompBrief Daily Digest lists the newest executive and director compensation disclosures as companies file them. Or order Crinetics Pharmaceuticals's full Executive Compensation Report with peer benchmarking.
How this record is built
Every figure on this page is one figure from a public SEC filing, printed as the filing states it and cited to the document. Compensation totals are Crinetics Pharmaceuticals's own disclosed totals, not summed by Velarion. Insider transactions are read from Form 4 filings and cover every line filed since the most recent proxy. Nothing is estimated by Velarion; where the company does not disclose a value the cell reads "—", and a section appears only where the company discloses the data. Corrections: records@velarion.ai.
Order CRNX
Add the email the receipt and the PDF go to, then press the report you want. Each button opens its own card payment on Stripe.